Bone marrow stromal cells (in red) infused into the spinal cord of mice with nerve injuries migrate to the site of injury and are still present four weeks after treatment. Photo credit – Gang Chen, Duke University
Chronic pain caused by the nerve damage of type 2 diabetes, surgical amputation, chemotherapy and other conditions is especially intractable because it resists painkilling medications.
But in a study on mice, a Duke University team has shown that injections of stem cells from bone marrow might be able to relieve this type of neuropathic pain. The researchers say their findings, which appear July 13 in the Journal of Clinical Investigation, may also advance cell-based therapies in chronic pain conditions, lower back pain and spinal cord injuries.
The team used a type of stem cell known as bone marrow stromal cells (BMSCs), which are known to produce an array of healing factors and can be coaxed into forming most other types of cells in the body.
Stromal cells are already being tested in small-scale clinical studies of people with inflammatory bowel disease, heart damage and stroke. They have also shown promise for treating pain. However, it’s not clear how they work.
“Based on these new results, we have the know-how and we can further engineer and improve the cells to maximize their beneficial effects,” said Ru-Rong Ji, professor of anesthesiology and neurobiology in the Duke School of Medicine.
In his team’s study, the researchers used stromal cells to treat mice with pain caused by nerve damage. They delivered the cells by a lumbar puncture, infusing them into the fluid that bathes the spinal cord.
Mice treated with the bone marrow stromal cells were much less sensitive to painful stimuli after their nerve injury compared with the untreated mice, the researchers found.
“This analgesic effect was amazing,” Ji said. “Normally, if you give an analgesic, you see pain relief for a few hours, at most a few days. But with bone marrow stem cells, after a single injection we saw pain relief over four to five weeks.”
Pictures of the animals’ spinal cords showed that the injected stem cells had set up shop alongside the nerve cells in the spinal cord.
To understand how the stem cells alleviated pain, the researchers measured levels of anti-inflammatory molecules that had been previously linked to pain, finding that one in particular, TGF-?1, was present in higher amounts in the spinal fluid of the stem cell-treated animals compared with the untreated animals.
TGF-?1 is a protein that is typically secreted by immune cells and is common throughout the body. Research has shown that people with chronic pain have too little TGF-?1, Ji said.
In the new study, chemically neutralizing TGF-?1 reversed the pain-killing benefit of the BMSCs, suggesting that the secretion of this protein was a major reason why the cells helped with pain. Injecting TGF-?1 directly into spinal cord fluid provides relief too, but only for a few hours, Ji said.
By contrast, bone marrow stromal cells stay on site for as much as three months after the infusion, the scientists found. This is the right length of time, Ji said, because if the stem cells stayed permanently there could be risk of them becoming cancerous.
Importantly, BMSCs also migrate to the site of injury. That’s because a molecule emitted from the injured nerve cells called CXCL12 — which has also previously been linked to neuropathic pain — acts as a homing signal of sorts, attracting the stem cells.
Read more: Stem Cells Provide Lasting Pain Relief in Mice
The Latest on: Neuropathic pain
via Google News
The Latest on: Neuropathic pain
- Ouch: Eliem’s pain drug fails second PhII trial, gets scrappedon August 2, 2022 at 7:52 am
Eliem Therapeutics' lead candidate, ETX-810, failed a Phase II study for diabetic nerve pain, buckling the greater Seattle-based biotech’s stock by over half. At the time, Eliem CEO and president Bob ...
- Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setbackon August 2, 2022 at 4:58 am
Eliem Therapeutics Inc (NASDAQ: ELYM) has reported results from its Phase 2a trial investigating ETX-810 for lumbosacral radicular pain (LSRP). In the study, ETX-810 did not achieve statistically ...
- Nerve Control 911 Reviews (USA): Best Nerve Pain Relief Supplement From PhytAge Labson July 31, 2022 at 3:37 am
The nervous system is a complicated but necessary part of the body. It allows for sensory communication and movement in animals, even though it may be composed entirely of nerves made up of neurons or ...
- Undefined Refractory Pain Is Pushing Pain Treatment Pipelineon July 28, 2022 at 8:18 am
With gaps in defining refractory pain (is it the same as chronic pain?), both physicians and researchers are focusing on underlying pathologies and treatment options beyond opioids to help patients.
- Neuropathic Pain Pipeline Market Is Set to Fly High in Years to Come with Top Countries Data | Exclusive Report Spread Across 104 Pageson July 27, 2022 at 9:23 pm
Neuropathic Pain Pipeline Market Research Report is spread across 104 Pages and provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche sector.
- Preclinical Ketamine Trial Shows Positive Results For Pain Conditions Like Fibromyalgia And Arthritison July 27, 2022 at 11:05 am
Biotech psychedelics researcher and developer Silo Pharma Inc. (OTCQB: SILO) announced its topically-administered proprietary ketamine obtained a positive outcome in a recent preclinical study.
- Vertex Advances VX-548 in Acute and Neuropathic Painon July 22, 2022 at 5:00 am
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that following the positive Phase 2 results earlier this year and having reached agreement on the design of the pivotal development ...
- Innovative approach to treating chronic pain receives $5 million from NIHon July 21, 2022 at 6:18 am
UVA Health researchers are pioneering a new way to treat Their innovative approach will receive more than $5 million from the National Institutes of Health to fund a clinical trial to develop brain ...
- New approach offers hope to chronic pain patientson July 20, 2022 at 1:58 pm
It is intended to raise pain tolerance and offer an alternative to medication for chronic nerve pain management. Dr. Jeff Elias of the UVA School of Medicine’s Department of Neurological Surgery and ...
- Pathophysiological Mechanisms of Neuropathic Painon July 15, 2022 at 5:00 pm
At the bedside examination, neuropathic pain can been distinguished from spontaneous pain, (i.e., stimulus independent) and provoked pain. [70] Spontaneous pain can have several different qualities.
via Bing News